Phaseline

Targets › TPK1

TPK1 (Thiamine pyrophosphokinase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Cardiovascular; next expected readout Jun 2027.

Catalyzes the phosphorylation of thiamine to thiamine pyrophosphate (TPP) utilizing UTP and therefore links the biosynthesis of TPP to pyrimidines metabolism. By producing thiamine pyrophosphate, a cofactor of the mitochondrial pyruvate dehydrogenase indirectly regulates pyruvate oxidation and lipogenesis. (UniProt, Q9H3S4)

Open in Phaseline: the race on TPK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hamilton Health Sciences CorporationThiamine Mononitrate
Vitamin B1 (thiamine) cofactor involved in energy metabolism
TPK1Phase 3Heart FailureJun 2027

Conditions

Heart Failure (1)

Modalities

small molecule (1)

Companies

Hamilton Health Sciences Corporation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.